Fresenius Kabi expands its portfolio of critical care medicine by launching Lacosamide Injection, USP, a generic equivalent to VIMPAT® in the U.S. 

Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in the U.S. beginning today. 

* VIMPAT® is a registered trademark of UCB, Inc.

Fresenius Kabi expands its portfolio of critical care medicine by launching Lacosamide Injection, USP, a generic equivalent to VIMPAT® in the U.S. 

Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in the U.S. beginning today. 

* VIMPAT® is a registered trademark of UCB, Inc.

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has entered the Dow Jones Sustainability World Index. Additionally, the company has been included for the 13th time in the Dow Jones Sustainability Index (DJSI) Europe. Fresenius Medical Care achieved an improved rating in most of the evaluated categories, and was awarded maximum scores for its environmental and social reporting. The company was also awarded significantly higher scores in the areas of occupational health and safety, talent attraction and retention, and customer relationship management.

“To us, successful sustainability management means creating lasting economic, environmental and social value,” said Helen Giza, CEO of Fresenius Medical Care. “We are proud that the DJSI has recognized our efforts to integrate sustainable actions systematically into our company.”

To compile the Dow Jones Sustainability Indexes, the international financial services company S&P Global evaluates the environmental, social and economic performance of companies. The 10 percent of global companies with the highest evaluations form the DJSI World. The DJSI Europe index is composed of the top 20 percent of the companies headquartered in Europe.

You can find an overview of Fresenius Medical Care’s progress in sustainability here.
 

In this year's ranking, CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 680 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

The U.S. Food and Drug Administration (FDA) has approved Fresenius Kabi’s biosimilar Idacio®, a citrate-free formulation of adalimumab. Idacio® (adalimumab) is approved for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira®**. 

With Idacio Fresenius Kabi expands its U.S. biosimilars portfolio focused on immunology and oncology. It is the company’s second approved biosimilar in the U.S. launching from July 2023 in accordance with the relevant patent settlement agreement with Abbvie. 

* Idacio® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries
**Humira® is a registered trademark of AbbVie, Inc. 
 

In this year's ranking, CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 680 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

The U.S. Food and Drug Administration (FDA) has approved Fresenius Kabi’s biosimilar Idacio®, a citrate-free formulation of adalimumab. Idacio® (adalimumab) is approved for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira®**. 

With Idacio Fresenius Kabi expands its U.S. biosimilars portfolio focused on immunology and oncology. It is the company’s second approved U.S. biosimilar launching from July 2023 in accordance with the relevant patent settlement agreement with Abbvie. 

* Idacio® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries
**Humira® is a registered trademark of AbbVie, Inc. 
 

Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent of companies based on S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Occupational Health and Safety, Climate Strategy, as well as Risk and Crisis Management. 

Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent of companies based on S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Occupational Health and Safety, Climate Strategy, as well as Risk and Crisis Management.